|  |
| --- |
| **Appendix 1:** **Demographic and Risk Behavior Characteristics of MSM Seen at San Francisco City Clinic (SFCC) between 9/1/2012 and 6/30/2016, Described by Case/Control Statusa** |
|  | **Cases** **Number (Percent)** | **Controls** **Number (Percent)** |
| **Total Number** | 161 | 477 |
| **Age distribution:**16-25 years26-35 years36-45 years46-55 years>55 years | 47 (29.2) | 141 (29.6) |
| 60 (37.3) | 175 (36.7) |
| 31 (19.3) | 97 (20.3) |
| 18 (11.2) | 50 (10.5) |
| 5 (3.1) | 14 (2.9) |
| **Race distribution:**African-AmericanAsian/Pacific IslanderHispanicWhite Other  | 23 (14.3) | 44 (9.2) |
| 18 (11.2) | 80 (16.8) |
| 49 (30.4) | 133 (27.9) |
| 70 (43.5) | 214 (44.9) |
| 1 (0.6) | 6 (1.3) |
| **Sexual orientation:**BisexualGayStraight | 18 (11.2) | 68 (14.4) |
| 141 (87.6) | 383 (80.8) |
| 2 (1.2) | 23 (4.9) |
| **Sexually transmitted disease (STD)b prior to baseline:**YesNo | 84 (52.2) | 198 (41.5) |
| 77 (47.8) | 279 (58.5) |
| **STD during study interval:** YesNo | 106 (65.8) | 218 (45.7) |
| 55 (34.2) | 259 (54.3) |
| **Number of male partners in last 3 months:** None1-2 partners3-7 partners8-15 partners>15 partners  | 1 (0.6) | 12 (2.7) |
| 39 (25.0) | 156 (34.5) |
| 58 (37.2) | 196 (43.4) |
| 31 (19.9) | 56 (12.4) |
| 27 (17.3) | 32 (7.1) |
| **HIV positive partner(s):**YesNo | 53 (39.9) | 94 (23.6) |
| 80 (60.2) | 305 (76.4) |
| **Total # CRAIc partners in last 3 months:**None1-2 partners3-10 partners | 53 (34.0) | 236 (53.5) |
| 68 (43.6) | 163 (37.0) |
| 35 (22.4) | 42 (9.5) |
| **Total # CIAId partners in last 3 months:** None1-2 partners3-10 partners  | 53 (34.4) | 207 (47.2) |
| 63 (40.9) | 188 (42.8) |
| 38 (24.7) | 44 (10.0) |
| **Any anal receptive sex in last 3 months:**YesNo | 132 (84.1) | 334 (74.7) |
| 25 (15.9) | 113 (25.3) |
| **Received money or drugs for sex in last 12 months:**YesNo | 14 (8.7) | 16 (3.4) |
| 147 (91.3) | 461 (96.7) |
| **Gave money or drugs for sex in last 12 months:**YesNo | 7 (4.4) | 15 (3.1) |
| 154 (95.7) | 462 (96.9) |
| **Methamphetamine use in last 12 months:**YesNo | 40 (24.8) | 27 (5.7) |
| 121 (75.2) | 450 (94.3) |
| **Intravenous Drug Use in last 12 months:**YesNo | 17 (10.6) | 7 (1.5) |
| 144 (89.4) | 470 (98.5) |
| **Ever took Pre-Exposure Prophylaxis (PrEP)** | 20 (12.4) | 117 (24.5) |
| **Took Post-Exposure Prophylaxis (PEP) Only** | 33 (20.5) | 65 (13.6) |
| **Took Neither PrEP nor PEP** | 108 (67.1) | 295 (61.8) |

aAll risk behavior characteristics are as reported during the first visit in the study interval, with the exception of “STDs during study interval,” which refers to diagnosed STDs occurring within the study dates.

bSTD = case of gonorrhea, chlamydia, or syphilis of any stage diagnosed either at SFCC or via San Francisco Department of Public Health STD surveillance

cCRAI = condomless receptive anal intercourse

dCIAI = condomless insertive anal intercourse

|  |
| --- |
| **Appendix 2: Odds of HIV seroconversion based on exposure to PrEP-only, PEP-only, both PrEP and PEP, or Neither at at San Francisco City Clinic (SFCC) between 9/1/2012 and 6/30/2016a** |
| **Category (number of patients, percent of study population)** | **OR** | **Confidence Interval** | **P-Value** |
| PrEP Only (96, 15.1%) | 0.50 | 0.25-0.93 | 0.03 |
| PEP Only (98, 15.4%) | 1.35 | 0.82-2.17 | 0.25 |
| Both PrEP and PEP (41, 6.4%) | 0.38 | 0.11-1.02 | 0.05 |
| Neither PrEP nor PEP (403, 63%) | 1.00 | Referent  |  |